Sang Taek Kim, MD, PhD
Assistant ProfessorCards
About
Research
Publications
2026
Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis
Kim S, Bass A. Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis. Arthritis & Rheumatology 2026, 10.1002/art.70128. PMID: 41800958, PMCID: PMC13035336, DOI: 10.1002/art.70128.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2025
Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy
Li Y, Kim S, Tannir N, Lu H. Sicca Syndrome Induced by Immune Checkpoint Inhibitor Therapy. 2025, 425-431. DOI: 10.1007/978-3-031-83533-9_53.Peer-Reviewed Original ResearchPolymyalgia Rheumatica-Like Syndrome Post Immune Checkpoint Inhibitor Therapy
Lu H, Bowman S, Linda Bobby N, Kim S, Msaouel P, Tayar J. Polymyalgia Rheumatica-Like Syndrome Post Immune Checkpoint Inhibitor Therapy. 2025, 433-438. DOI: 10.1007/978-3-031-83533-9_54.Peer-Reviewed Original ResearchThe Current and Future of Biomarkers of Immune Related Adverse Events
Bracamonte-Baran W, Kim S. The Current and Future of Biomarkers of Immune Related Adverse Events. Immunology And Allergy Clinics Of North America 2025, 45: 223-249. PMID: 40287170, DOI: 10.1016/j.iac.2025.01.010.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2024
Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series
Li Y, Msaouel P, Campbell M, Hwu P, Diab A, Kim S. Successful management of pre-existing psoriatic arthritis through targeting the IL-23/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series. RMD Open 2024, 10: e004308. PMID: 39214611, PMCID: PMC11367333, DOI: 10.1136/rmdopen-2024-004308.Peer-Reviewed Original ResearchAuthor Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu S, Wang J, Shah A, Tannir N, Campbell M, Gibbons D, Cascone T, Lu C, Blumenschein G, Altan M, Lim B, Valero V, Loghin M, Tu J, Westin S, Naing A, Garcia-Manero G, Abdel-Wahab N, Tawbi H, Hwu P, Oliva I, Davies M, Patel S, Zou J, Futreal A, Diab A, Wang L, Nurieva R. Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nature Communications 2024, 15: 5621. PMID: 38965214, PMCID: PMC11224259, DOI: 10.1038/s41467-024-49733-9.Commentaries, Editorials and LettersEmerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy
Turner N, Hamidi S, Ouni R, Rico R, Henderson Y, Puche M, Alekseev S, Colunga-Minutti J, Zafereo M, Lai S, Kim S, Cabanillas M, Nurieva R. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Frontiers In Immunology 2024, 15: 1369780. PMID: 38868771, PMCID: PMC11167082, DOI: 10.3389/fimmu.2024.1369780.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsThe Current and Future of Biomarkers of Immune Related Adverse Events
Kim S. The Current and Future of Biomarkers of Immune Related Adverse Events. Rheumatic Disease Clinics Of North America 2024, 50: 201-227. PMID: 38670721, PMCID: PMC11232920, DOI: 10.1016/j.rdc.2024.01.004.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2023
Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept
Aminu M, Daver N, Godoy M, Shroff G, Wu C, Torre-Sada L, Goizueta A, Shannon V, Faiz S, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim S, Kontoyiannis D, Khawaja F, Chung C, Wu J, Sheshadri A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Frontiers In Immunology 2023, 14: 1249511. PMID: 37841255, PMCID: PMC10570510, DOI: 10.3389/fimmu.2023.1249511.Peer-Reviewed Original ResearchLearning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors
Lopez-Olivo M, Kachira J, Buni M, Kim S, Lu H, Tayar J, Duhon G, Ruiz J, Bingham C, Calabrese C, Volk R, Suarez-Almazor M. Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors. Cancers 2023, 15: 4004. PMID: 37568819, PMCID: PMC10416973, DOI: 10.3390/cancers15154004.Peer-Reviewed Original Research
Clinical Care
Overview
Sang Taek Kim, MD, PhD, is a rheumatologist who cares for people with autoimmune conditions that affect the joints, muscles, bones, and other organs. He treats conditions including rheumatoid arthritis, lupus, psoriatic arthritis, gout, and vasculitis.
Dr. Kim offers a range of therapies to help relieve pain, reduce inflammation, and improve mobility and quality of life. In particular, he is experienced in managing rheumatology patients with preexisting or coexisting cancers.
Dr. Kim investigates how cancer immunotherapy can cause autoimmune complications, known as immune-related adverse events (irAEs). He works to develop optimal strategies for managing irAEs without compromising the efficacy of cancer immunotherapy.
Dr. Kim received his medical training from Yonsei University College of Medicine in South Korea. After completing his internal medicine training at Mount Sinai Hospital, he completed a rheumatology fellowship at Yale School of Medicine.
Clinical Specialties
Rheumatology; Internal Medicine
Board Certifications
Rheumatology
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2016
News
News
- May 02, 2025
Immunotherapy: Balancing Cancer Treatment Benefits and Risks
- November 13, 2023
Sang Taek Kim Returns to YSM to Lead Immunotherapy Adverse Events Program
- November 08, 2023
Yale Advances Rheumatology Research and Practice at American College of Rheumatology Convergence 2023
- August 16, 2023
Welcome New Postdocs, Postgrads, Fellows, Faculty & Staff! (August 2023)
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.